The Chemotherapy Sourcebook: Companion to 2r.e

Part 1 Principles of chemotherapy: scientific foundation of chemotherapy - the scientific basis of cancer chemotherapy, antineoplastic drug development, principles of pharmacology, drug resistance - the Norton-Simon hypothesis, drug resistance - the Goldie-Coldman hypothesis, adjuvant chemotherapy, combination chemotherapy, combined modality therapy, the design and interpretation of clinical trials, haematopoietic growth factors, biologic response modifiers - principles of immunotherapy, chemotherapy - circadian timing and toxicity; routes of administration - intraventricular therapy, intraperitoneal chemotherapy, continuous intravenous infusion chemotherapy, intraarterial therapy, perfusion therapy, bone marrow transplantation. Part 2 Chemotherapeutic drugs: covalent DNA-binding drugs; antimetabolites; non-covalent DNA-binding drugs; microtubule targeting drugs; taxanes; differentiating agents, hormonal agents; investigational drugs. Part 3 Management of drug toxicity: haematologic complications of cancer chemotherapy; oral toxicity; dermatological toxicity; extravasation; hypersensitivity reactions; ocular side effects of chemotherapy; the cardiotoxicity of chemotherapeutic drugs; antineoplastic drugs and pulmonary toxicity; gastrointestinal toxicity of chemotherapeutic agents; hepatotoxicity of chemotherapeutic agents; renal and electrolyte abnormalities due to chemotherapy; neurotoxicity of chemotherapeutic agents; vascular toxicity; second malignancies after chemotherapy; chemotherapy in pregnancy; gonadal toxicity and teratogenicity; toxicity of biologic response modifiers. Part 4 Combination chemotherapy programmes: combination chemotherapy programmes; central venous access for chemotherapy; safe handling of cytotoxic drugs - a review; stability and compatibility of intravenous oncology drugs; patient education; nursing implications in the administration of cancer chemotherapy. Part 5 Drug administration: myelodysplastic syndromes; myeloproliferative syndromes; the treatment of multiple myeloma and related plasma cell dyscrasias; appendix - WHO toxicity guidelines. Part 6 Current therapy of specific solid tumours: chemotherapy of melanoma; chemotherapy of primary brain tumours; head and neck cancer; chemotherapy of lung cancer; chemotherapy of breast cancer; chemotherapy of gastrointestinal cancer; chemotherapy of endocrine tumours; chemotherapy of genitourinary cancer; chemotherapy of gynaecologic cancer; sarcomas of bone and soft tissue; carcinoma of unknown primary site; paediatric solid tumours. Part 7 Chemotherapy of haematologic malignancies: Hodgkin's disease; non-Hodgkin's lymphoma; acute leukaemia in adults; chronic lymphocyte leukaemia and hairy cell leukaemia.